Results 241 to 250 of about 1,886,076 (260)

Regulation of adult stem cell quiescence and its functions in the maintenance of tissue integrity

Nature Reviews Molecular Cell Biology, 2023
Antoine de Morreé, Thomas A Rando
exaly  

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Lancet, The, 2022
M Ferrante, Remo Panaccione, Peter Bossuyt   +2 more
exaly  

Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis

Lancet, The, 2022
Johannes Schneider-Thoma, Konstantina Chalkou, Irene Bighelli   +2 more
exaly  

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Lancet, The, 2021
B G Feagan, Silvio Danese, Edward V Loftus   +2 more
exaly  

The evolution and maintenance of virulence in Staphylococcus aureus: a role for host-to-host transmission?

Nature Reviews Microbiology, 2006
Ruth C Massey, Malcolm Horsburgh, Gerard Lina   +2 more
exaly  

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Lancet, The, 2002
Stephen B Hanauer, Stefan Schreiber
exaly  

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Lancet, The, 2019
Athanasios Dimopoulos, Meral Beksac, Hartmut Goldschmidt   +2 more
exaly  

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Lancet, The, 2015
Anne M May, Cornelis J A Punt, Miriam Koopman   +2 more
exaly  

HP1 and the dynamics of heterochromatin maintenance

Nature Reviews Molecular Cell Biology, 2004
Genevieve Almouzni
exaly  

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

Lancet, The, 2005
Kristian Reich, Christopher Em Griffiths
exaly